	US 12,251,434 B2
	Target sequence of RNA virus and use thereof
Wenqiang Yu, Shanghai (CN); Zhenyan Li, Shanghai (CN); Jianqing Xu, Shanghai (CN); Hailin Wang, Shanghai (CN); Wei Li, Shanghai (CN); Cheng Lian, Shanghai (CN); and Peng Xu, Shanghai (CN)
Assigned to SHANGHAI PUBLIC HEALTH CLINICAL CENTER, Shanghai (CN); and Shanghai Yizhe Biotechnology Co., Ltd., Shanghai (CN)
Filed by SHANGHAI PUBLIC HEALTH CLINICAL CENTER, Shanghai (CN); and Shanghai Yizhe Biotechnology Co., Ltd., Shanghai (CN)
Filed on Nov. 4, 2021, as Appl. No. 17/453,574.
Prior Publication US 2023/0173054 A1, Jun. 8, 2023
Int. Cl. C07K 14/47 (2006.01); A61K 31/7088 (2006.01); A61K 39/12 (2006.01); A61P 31/14 (2006.01); C07K 4/00 (2006.01); C07K 14/00 (2006.01); C07K 14/005 (2006.01); C07K 14/435 (2006.01); C07K 16/18 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 31/7088 (2013.01); A61P 31/14 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01)]

7 Claims

1. A biomaterial related to a target sequence of a RNA virus, wherein the target sequence is a nucleic acid sequence fragment in the gene sequence in the RNA virus containing 20-40 bases and having not less than 95% similarity to human genome sequence, and the biomaterial is:

A) a DNA and/or RNA molecule that is complementary and paired to the target sequence of the RNA virus; or

B) an expression cassette, a recombinant vector, a recombinant microorganism, a recombinant cell line containing the target sequence of the RNA virus or the DNA molecule in A).